Argenica Therapeutics phase 2 trial update

Argenica Therapeutics Limited (ASX:AGN) has received a positive outcome from the Data Safety Monitoring Board (DSMB) for its Phase 2 clinical trial of ARG-007 in acute ischemic stroke patients. The DSMB has recommended the study to continue with no modifications required to the study protocol. To date, 43 patients have been dosed in the trial, representing 47% completion, with an anticipated completion of all 92 patients by the end of Q2 calendar year 2025.

Executive commentary on phase 2 trial progress

Dr Liz Dallimore, Managing Director of Argenica, expressed satisfaction with the DSMB's recommendation and the successful recruitment and dosing rates. Dr Dallimore stated, 'It is pleasing to see there were no dosing related adverse events reported to the DSMB, and that the trial can continue unchanged. We are equally pleased by the successful recruitment and dosing rates being achieved as these are currently exceeding our initial expectations.'

Summary of Argenica Therapeutics phase 2 trial update

Argenica Therapeutics (ASX:AGN) has received a positive outcome from the DSMB for its Phase 2 clinical trial of ARG-007 in acute ischemic stroke patients, with the recommendation to continue the study with no modifications to the protocol. The trial has dosed 43 patients to date, representing 47% completion, and is anticipated to complete dosing of all 92 patients by the end of Q2 calendar year 2025. Dr Liz Dallimore, Managing Director of Argenica, expressed satisfaction with the DSMB's recommendation and the successful recruitment and dosing rates, indicating optimism for the trial's progress.